Premium
MonoFIX‐VF, a new mono‐component factor IX concentrate: a single‐centre continuous‐infusion study
Author(s) -
EVANS G.,
COLLETT M.,
CAME N.,
LLOYD J.,
POWELL L.,
STREET A.
Publication year - 2002
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1046/j.1365-2516.2002.00663.x
Subject(s) - medicine , haemophilia b , factor ix , continuous infusion , haemophilia , surgery , anesthesia , haemophilia a
Summary. MonoFIX‐VF, a monocomponent factor IX concentrate, has replaced the use of Prothrombinex‐HT as the treatment of choice for patients with factor IX deficiency in Australia. The haemostatic effect of MonoFIX‐VF, administered by continuous infusion, was assessed in four subjects being treated for 10 bleeding episodes including five surgical procedures. MonoFIX‐VF was found to be a safe and effective treatment for patients with haemophilia B.